Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Resonetics acquires Aduro Laser
Resonetics announced that it has acquired Aduro Laser. The financial details of the deal were not disclosed.
“We are very excited to partner with Grayson Beck and Demian Backs, who have created raving fans with Aduro’s disruptive business model,” Tom Burns, Resonetics’ CEO, said. “We share a similar culture with an emphasis on innovation, speed and customer satisfaction. Prime Laser Cut tubing is already being adopted by leading companies in structural heart, peripheral vascular and minimally invasive surgery markets. Resonetics will expand capacity with a new facility, additional equipment and more engineering resources to keep lead times the best in the industry.” Read more
4. Bard lands new indication for its drug-coated balloon
C. R. Bard said today that its Lutonix 035 drug-coated balloon PTA catheter won premarket approval from the FDA and is available in the U.S.
The company’s Lutonix 035 device is the first drug-coated balloon approved in end-stage renal disease patients with stenotic lesions in dialysis arteriovenous fistulae. Bard’s DCB is also approved to treat superficial femoral artery and popliteal artery disease. Read more
3. Abbott wins FDA nod for HeartMate 3 pump
Abbott said today that the FDA approved its HeartMate 3 implantable pump for heart failure patients awaiting a transplant.
The approval is the latest for the HeartMate line of left ventricular assist devices first developed by Thoratec, which was later acquired by St. Jude Medical before a $25 billion merger brought it to Abbott earlier this year. Read more
2. Medtronic readies pivotal trial in renal denervation
Medtronic said today that it’s ready for a run at FDA approval for renal denervation in treating high blood pressure, more than three years after the failure of a high-profile clinical trial.
Back in January 2014, Fridley, Minn.-based Medtronic shocked medtech when it announced that the highly anticipated Symplicity HTN-3 trial, examining ablation of the around the renal arteries in treating hypertension, failed to meet its efficacy endpoint. The company suspended enrollment in its other Symplicity trials around the world and later took a $200 million write-down on its renal denervation assets. News of the trials failure reverberated throughout the medical device industry, prompting other companies to follow suit by either scaling back their RDN programs or spiking them altogether. Read more
1. ‘It’s in our DNA’: How Intuitive Surgical CEO Guthart plans to stay on top of the surgical robotics market
Intuitive Surgical has spent more than a decade dominating the robot-assisted surgery market, and longtime CEO Gary Guthart has no plans to cede that position, he tells MassDevice.com Executive Editor Brad Perriello in this special podcast.
Guthart said Sunnyvale, Calif.-based Intuitive stays focused on one criterion: “Where can we make a difference in outcomes?” Robotic surgery is intrinsic to the company’s genetic code, he said. Read more
The post MassDevice.com +5 | The top 5 medtech stories for August 28, 2017 appeared first on MassDevice.
from MassDevice http://ift.tt/2wiVOB5
Cap comentari:
Publica un comentari a l'entrada